array(40) {
  [0]=>
  string(4) "2090"
  ["article_id"]=>
  string(4) "2090"
  [1]=>
  string(91) "Pfizer gets FDA nod for Vyndaqel and Vyndamax to treat transthyretin amyloid cardiomyopathy"
  ["article_title"]=>
  string(91) "Pfizer gets FDA nod for Vyndaqel and Vyndamax to treat transthyretin amyloid cardiomyopathy"
  [2]=>
  string(150) "The approval has been granted for Vyndaqel and Vyndamax to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM"
  ["short_description"]=>
  string(150) "The approval has been granted for Vyndaqel and Vyndamax to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM"
  [3]=>
  string(643) "
The approval has been granted for Vyndaqel and Vyndamax to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. 
&#nl
The post Pfizer gets FDA nod for Vyndaqel and Vyndamax to treat transthyretin amyloid cardiomyopathy appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(643) "
The approval has been granted for Vyndaqel and Vyndamax to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. 
&#nl
The post Pfizer gets FDA nod for Vyndaqel and Vyndamax to treat transthyretin amyloid cardiomyopathy appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(92) "https://www.pharmaceutical-business-review.com/news/pfizer-vyndaqel-vyndamax-cardiomyopathy/"
  ["blog_url"]=>
  string(92) "https://www.pharmaceutical-business-review.com/news/pfizer-vyndaqel-vyndamax-cardiomyopathy/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:25"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:25"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2089"
  ["article_id"]=>
  string(4) "2089"
  [1]=>
  string(64) "Ligand acquires milestone and royalty rights to SB206 from Novan"
  ["article_title"]=>
  string(64) "Ligand acquires milestone and royalty rights to SB206 from Novan"
  [2]=>
  string(153) "Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20 &#nlThe post Ligand ac"
  ["short_description"]=>
  string(153) "Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20 &#nlThe post Ligand ac"
  [3]=>
  string(537) "
Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20 
&#nl
The post Ligand acquires milestone and royalty rights to SB206 from Novan appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(537) "
Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20 
&#nl
The post Ligand acquires milestone and royalty rights to SB206 from Novan appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(123) "https://www.pharmaceutical-business-review.com/news/deals/ligand-acquires-milestone-and-royalty-rights-to-sb206-from-novan/"
  ["blog_url"]=>
  string(123) "https://www.pharmaceutical-business-review.com/news/deals/ligand-acquires-milestone-and-royalty-rights-to-sb206-from-novan/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:25"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:25"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2088"
  ["article_id"]=>
  string(4) "2088"
  [1]=>
  string(89) "PharmaCyte Biotech advances manufacturing process for clinical trial in pancreatic cancer"
  ["article_title"]=>
  string(89) "PharmaCyte Biotech advances manufacturing process for clinical trial in pancreatic cancer"
  [2]=>
  string(155) "Since PharmaCyte’s last press release describing the manufacturing process for its clinical trial product and the testing of that product, the data "
  ["short_description"]=>
  string(155) "Since PharmaCyte’s last press release describing the manufacturing process for its clinical trial product and the testing of that product, the data "
  [3]=>
  string(645) "
Since PharmaCyte’s last press release describing the manufacturing process for its clinical trial product and the testing of that product, the data from the manufacturing process has been 
&#nl
The post PharmaCyte Biotech advances manufacturing process for clinical trial in pancreatic cancer appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(645) "
Since PharmaCyte’s last press release describing the manufacturing process for its clinical trial product and the testing of that product, the data from the manufacturing process has been 
&#nl
The post PharmaCyte Biotech advances manufacturing process for clinical trial in pancreatic cancer appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(142) "https://www.pharmaceutical-business-review.com/news/pharmacyte-biotech-advances-manufacturing-process-for-clinical-trial-in-pancreatic-cancer/"
  ["blog_url"]=>
  string(142) "https://www.pharmaceutical-business-review.com/news/pharmacyte-biotech-advances-manufacturing-process-for-clinical-trial-in-pancreatic-cancer/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:25"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:25"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2087"
  ["article_id"]=>
  string(4) "2087"
  [1]=>
  string(87) "AstraZeneca’s blood cancer drug Calquence improves PFS in phase III Ascend trial"
  ["article_title"]=>
  string(87) "AstraZeneca’s blood cancer drug Calquence improves PFS in phase III Ascend trial"
  [2]=>
  string(150) "The trial results demonstrated a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Calquence mon"
  ["short_description"]=>
  string(150) "The trial results demonstrated a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Calquence mon"
  [3]=>
  string(649) "
The trial results demonstrated a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Calquence monotherapy compared against a combination regimen of rituximab plus physician’s choice of idelalisib 
&#nl
The post AstraZeneca’s blood cancer drug Calquence improves PFS in phase III Ascend trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(649) "
The trial results demonstrated a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Calquence monotherapy compared against a combination regimen of rituximab plus physician’s choice of idelalisib 
&#nl
The post AstraZeneca’s blood cancer drug Calquence improves PFS in phase III Ascend trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/astrazenecas-blood-cancer-calquence/"
  ["blog_url"]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/astrazenecas-blood-cancer-calquence/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:25"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:25"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2086"
  ["article_id"]=>
  string(4) "2086"
  [1]=>
  string(87) "Roche’s Kadcyla gets FDA nod for adjuvant treatment of HER2+ early breast cancer"
  ["article_title"]=>
  string(87) "Roche’s Kadcyla gets FDA nod for adjuvant treatment of HER2+ early breast cancer"
  [2]=>
  string(150) "The latest approval for Kadcyla is for HER2-positive early breast cancer patients with residual invasive disease after being subjected to neoadjuvant "
  ["short_description"]=>
  string(150) "The latest approval for Kadcyla is for HER2-positive early breast cancer patients with residual invasive disease after being subjected to neoadjuvant "
  [3]=>
  string(589) "
The latest approval for Kadcyla is for HER2-positive early breast cancer patients with residual invasive disease after being subjected to neoadjuvant treatment with taxane and Herceptin (trastuzumab). The 
&#nl
The post Roche’s Kadcyla gets FDA nod for adjuvant treatment of HER2+ early breast cancer appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(589) "
The latest approval for Kadcyla is for HER2-positive early breast cancer patients with residual invasive disease after being subjected to neoadjuvant treatment with taxane and Herceptin (trastuzumab). The 
&#nl
The post Roche’s Kadcyla gets FDA nod for adjuvant treatment of HER2+ early breast cancer appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/roche-kadcyla-fda-approval/"
  ["blog_url"]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/roche-kadcyla-fda-approval/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:25"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:25"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2085"
  ["article_id"]=>
  string(4) "2085"
  [1]=>
  string(77) "Merck’s BELSOMRA C-IV meets primary efficacy endpoint in phase 3 trial"
  ["article_title"]=>
  string(77) "Merck’s BELSOMRA C-IV meets primary efficacy endpoint in phase 3 trial"
  [2]=>
  string(155) "This is the first dedicated Phase 3 polysomnography study of an insomnia medication in people with mild-to-moderate Alzheimer’s disease dementia, an"
  ["short_description"]=>
  string(155) "This is the first dedicated Phase 3 polysomnography study of an insomnia medication in people with mild-to-moderate Alzheimer’s disease dementia, an"
  [3]=>
  string(614) "
This is the first dedicated Phase 3 polysomnography study of an insomnia medication in people with mild-to-moderate Alzheimer’s disease dementia, and in the trial, BELSOMRA met its primary 
&#nl
The post Merck’s BELSOMRA C-IV meets primary efficacy endpoint in phase 3 trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(614) "
This is the first dedicated Phase 3 polysomnography study of an insomnia medication in people with mild-to-moderate Alzheimer’s disease dementia, and in the trial, BELSOMRA met its primary 
&#nl
The post Merck’s BELSOMRA C-IV meets primary efficacy endpoint in phase 3 trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(122) "https://www.pharmaceutical-business-review.com/news/mercks-belsomra-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial/"
  ["blog_url"]=>
  string(122) "https://www.pharmaceutical-business-review.com/news/mercks-belsomra-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:25"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:25"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2084"
  ["article_id"]=>
  string(4) "2084"
  [1]=>
  string(106) "European Commission approves LORVIQU for certain adult patients with previously-treated ALK-positive NSCLC"
  ["article_title"]=>
  string(106) "European Commission approves LORVIQU for certain adult patients with previously-treated ALK-positive NSCLC"
  [2]=>
  string(154) "“Pfizer has worked to pioneer biomarker-driven medicine for patients with ALK-positive non-small cell lung cancer and we continue to advance patient"
  ["short_description"]=>
  string(154) "“Pfizer has worked to pioneer biomarker-driven medicine for patients with ALK-positive non-small cell lung cancer and we continue to advance patient"
  [3]=>
  string(687) "
“Pfizer has worked to pioneer biomarker-driven medicine for patients with ALK-positive non-small cell lung cancer and we continue to advance patient care with the approval of LORVIQUA,” said 
&#nl
The post European Commission approves LORVIQU for certain adult patients with previously-treated ALK-positive NSCLC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(687) "
“Pfizer has worked to pioneer biomarker-driven medicine for patients with ALK-positive non-small cell lung cancer and we continue to advance patient care with the approval of LORVIQUA,” said 
&#nl
The post European Commission approves LORVIQU for certain adult patients with previously-treated ALK-positive NSCLC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(159) "https://www.pharmaceutical-business-review.com/news/european-commission-approves-lorviqu-for-certain-adult-patients-with-previously-treated-alk-positive-nsclc/"
  ["blog_url"]=>
  string(159) "https://www.pharmaceutical-business-review.com/news/european-commission-approves-lorviqu-for-certain-adult-patients-with-previously-treated-alk-positive-nsclc/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:24"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2083"
  ["article_id"]=>
  string(4) "2083"
  [1]=>
  string(62) "Novartis to buy Takeda’s dry eye drug Xiidra for $3.4bn"
  ["article_title"]=>
  string(62) "Novartis to buy Takeda’s dry eye drug Xiidra for $3.4bn"
  [2]=>
  string(150) "As per terms of the agreement, Takeda is also eligible to secure up to an additional $1.9bn in potential milestone payments from Novartis along with $"
  ["short_description"]=>
  string(150) "As per terms of the agreement, Takeda is also eligible to secure up to an additional $1.9bn in potential milestone payments from Novartis along with $"
  [3]=>
  string(527) "
As per terms of the agreement, Takeda is also eligible to secure up to an additional $1.9bn in potential milestone payments from Novartis along with $3.4bn upfront payment 
&#nl
The post Novartis to buy Takeda’s dry eye drug Xiidra for $3.4bn appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(527) "
As per terms of the agreement, Takeda is also eligible to secure up to an additional $1.9bn in potential milestone payments from Novartis along with $3.4bn upfront payment 
&#nl
The post Novartis to buy Takeda’s dry eye drug Xiidra for $3.4bn appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(75) "https://www.pharmaceutical-business-review.com/news/novartis-takeda-xiidra/"
  ["blog_url"]=>
  string(75) "https://www.pharmaceutical-business-review.com/news/novartis-takeda-xiidra/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:24"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3079"
  ["article_id"]=>
  string(4) "3079"
  [1]=>
  string(115) "Essentials Of USP Microbiology - Reading Between the Lines of the USP General and Information Microbiology Chapters"
  ["article_title"]=>
  string(115) "Essentials Of USP Microbiology - Reading Between the Lines of the USP General and Information Microbiology Chapters"
  [2]=>
  string(150) "The objective of this two day "Essentials of USP Microbiology" seminar is to explore USP General and General Information Chapters to learn w"
  ["short_description"]=>
  string(150) "The objective of this two day "Essentials of USP Microbiology" seminar is to explore USP General and General Information Chapters to learn w"
  [3]=>
  string(487) "The objective of this two day "Essentials of USP Microbiology" seminar is to explore USP General and General Information Chapters to learn which are available and to confirm that those that you are using are being used correctly. &#nlVarious team exercises will be conducted to allow the participants to use these USP documents to solve "real life" problems. Plan to bring a cross-functional group of your personnel to attend this invaluable two day seminar."
  ["description"]=>
  string(487) "The objective of this two day "Essentials of USP Microbiology" seminar is to explore USP General and General Information Chapters to learn which are available and to confirm that those that you are using are being used correctly. &#nlVarious team exercises will be conducted to allow the participants to use these USP documents to solve "real life" problems. Plan to bring a cross-functional group of your personnel to attend this invaluable two day seminar."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(162) "
https://www.pharmiweb.com/event/essentials-of-usp-microbiology-reading-between-the-lines-of-the-usp-general-and-information-microbiology-chapters                "
  ["blog_url"]=>
  string(162) "
https://www.pharmiweb.com/event/essentials-of-usp-microbiology-reading-between-the-lines-of-the-usp-general-and-information-microbiology-chapters                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:58:09"
  ["create_at"]=>
  string(19) "2019-06-09 21:58:09"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3080"
  ["article_id"]=>
  string(4) "3080"
  [1]=>
  string(44) "14th Euro-Global Gastroenterology Conference"
  ["article_title"]=>
  string(44) "14th Euro-Global Gastroenterology Conference"
  [2]=>
  string(162) "14th Euro-Global Gastroenterology Conference&#nl&#nlJuly 08-09, 2019 Zürich, Switzerland&#nl&#nl      &"
  ["short_description"]=>
  string(162) "14th Euro-Global Gastroenterology Conference&#nl&#nlJuly 08-09, 2019 Zürich, Switzerland&#nl&#nl      &"
  [3]=>
  string(689) "14th Euro-Global Gastroenterology Conference&#nl&#nlJuly 08-09, 2019 Zürich, Switzerland&#nl&#nl                                   https://europegastroenterology.gastroconferences.com/  &#nl&#nlTheme: “Future Perspectives and shaping trends in Gastroenterology”&#nl&#nlGastro Congress 2019&#nl&#nlWe cordially invite all the interested participa…"
  ["description"]=>
  string(689) "14th Euro-Global Gastroenterology Conference&#nl&#nlJuly 08-09, 2019 Zürich, Switzerland&#nl&#nl                                   https://europegastroenterology.gastroconferences.com/  &#nl&#nlTheme: “Future Perspectives and shaping trends in Gastroenterology”&#nl&#nlGastro Congress 2019&#nl&#nlWe cordially invite all the interested participa…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(93) "
https://www.pharmiweb.com/event/14th-euro-global-gastroenterology-conference                "
  ["blog_url"]=>
  string(93) "
https://www.pharmiweb.com/event/14th-euro-global-gastroenterology-conference                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:58:09"
  ["create_at"]=>
  string(19) "2019-06-09 21:58:09"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3081"
  ["article_id"]=>
  string(4) "3081"
  [1]=>
  string(38) "Clinical Trial Regulatory Requirements"
  ["article_title"]=>
  string(38) "Clinical Trial Regulatory Requirements"
  [2]=>
  string(162) "Course overview&#nl&#nlAre you up to date with the regulatory requirements for clinical research?&#nl&#nlDo you understand the impact and new requirements of the "
  ["short_description"]=>
  string(162) "Course overview&#nl&#nlAre you up to date with the regulatory requirements for clinical research?&#nl&#nlDo you understand the impact and new requirements of the "
  [3]=>
  string(536) "Course overview&#nl&#nlAre you up to date with the regulatory requirements for clinical research?&#nl&#nlDo you understand the impact and new requirements of the EU Clinical Trials Regulation and delegated acts and guidelines?&#nl&#nlThis course will take you through the key regulatory and guideline requirements for clinical research in Europe, including the new EU Clinical Trial Regulation, the new ICH GCP (R2) guideline and existing Directive requirements. Key US requirements which impact o…"
  ["description"]=>
  string(536) "Course overview&#nl&#nlAre you up to date with the regulatory requirements for clinical research?&#nl&#nlDo you understand the impact and new requirements of the EU Clinical Trials Regulation and delegated acts and guidelines?&#nl&#nlThis course will take you through the key regulatory and guideline requirements for clinical research in Europe, including the new EU Clinical Trial Regulation, the new ICH GCP (R2) guideline and existing Directive requirements. Key US requirements which impact o…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(87) "
https://www.pharmiweb.com/event/clinical-trial-regulatory-requirements                "
  ["blog_url"]=>
  string(87) "
https://www.pharmiweb.com/event/clinical-trial-regulatory-requirements                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:58:09"
  ["create_at"]=>
  string(19) "2019-06-09 21:58:09"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3082"
  ["article_id"]=>
  string(4) "3082"
  [1]=>
  string(63) "30th International Conference on Sleep Disorders and Psychiatry"
  ["article_title"]=>
  string(63) "30th International Conference on Sleep Disorders and Psychiatry"
  [2]=>
  string(162) "30th International Conference on Sleep Disorders and Psychiatry&#nl&#nlSleep Congress 2019&#nl&#nlTheme: New Directions and Global Perspectives in Neurology, Psyc"
  ["short_description"]=>
  string(162) "30th International Conference on Sleep Disorders and Psychiatry&#nl&#nlSleep Congress 2019&#nl&#nlTheme: New Directions and Global Perspectives in Neurology, Psyc"
  [3]=>
  string(536) "30th International Conference on Sleep Disorders and Psychiatry&#nl&#nlSleep Congress 2019&#nl&#nlTheme: New Directions and Global Perspectives in Neurology, Psychiatry & Sleep Disorders&#nl&#nlVienna, Austria | July 08-09, 2019&#nl&#nlEuroscicon Ltd takes immense pleasure in inviting the scientists, researchers, professors, delegates across the continents to its upcoming Sleep Congress 2019.&#nl&#nlSleep Congress 2019 is to gathering people in academia and society interested in Psychiatry to share the latest t…"
  ["description"]=>
  string(536) "30th International Conference on Sleep Disorders and Psychiatry&#nl&#nlSleep Congress 2019&#nl&#nlTheme: New Directions and Global Perspectives in Neurology, Psychiatry & Sleep Disorders&#nl&#nlVienna, Austria | July 08-09, 2019&#nl&#nlEuroscicon Ltd takes immense pleasure in inviting the scientists, researchers, professors, delegates across the continents to its upcoming Sleep Congress 2019.&#nl&#nlSleep Congress 2019 is to gathering people in academia and society interested in Psychiatry to share the latest t…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(112) "
https://www.pharmiweb.com/event/30th-international-conference-on-sleep-disorders-and-psychiatry                "
  ["blog_url"]=>
  string(112) "
https://www.pharmiweb.com/event/30th-international-conference-on-sleep-disorders-and-psychiatry                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:58:09"
  ["create_at"]=>
  string(19) "2019-06-09 21:58:09"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}